The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 2, 2009, Pages 214-219

  Torres, K C L ^a   Souza, B R ^a   Miranda, D M ^a   Nicolato, R ^a   Neves, F S ^a   Barros, A G A ^a   Dutra, W O ^b   Gollob, K J ^b   Correa, H ^a   Romano Silva, M A ^a  

^a Faculdade de Medicina   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bipolar disorder; DARPP 32; Dopamine; Flow cytometry; Leukocytes; Peripheral blood mononuclear cells (PBMC); Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; CYCLIC AMP; DOPAMINE; MESSENGER RNA; PHOSPHOPROTEIN DARPP 32;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; B LYMPHOCYTE; BIPOLAR DISORDER; BLOOD CELL; BRAIN TISSUE; CD4+ T LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE SYSTEM; LEUKOCYTE; MALE; MEDICAL LITERATURE; MONOCYTE; NATURAL KILLER CELL; NERVOUS SYSTEM; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ADULT; AGED; BIOLOGICAL MARKERS; BIPOLAR DISORDER; CD4-POSITIVE T-LYMPHOCYTES; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; LEUKOCYTES; LYMPHOCYTES; MALE; MIDDLE AGED; MONOCYTES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 60249102897     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.10.020     Document Type: Article

References (43)

1. Albert K.A., Hemmings Jr. H.C., Adamo A.I., Potkin S.G., Akbarian S., Sandman C.A., et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 59 (2002) 705-712
2. Breunis M.N., Kupka R.W., Nolen W.A., Suppes T., Denicoff K.D., Leverich G.S., et al., Drexhage H.A. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 53 (2003) 157-165
3. Caldwell C.L., Irwin M., and Lohr J. Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 30 (1991) 1131-1138
4. Centorrino F., Eakin M., Bahk W.M., Kelleher J.P., Goren J., Salvatore P., et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry 159 (2002) 1932-1935
5. Du X., Tang Y., Xu H., Lit L., Walker W., Ashwood P., et al. Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics 87 (2006) 693-703
6. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36 (2004) 131-137
7. Ganguli R., Rabin B.S., Kelly R.H., Lyte M., and Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann N Y Acad Sci 496 (1987) 676-685
8. Gao K., Gajwani P., Elhaj O., and Calabrese J.R. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 66 (2005) 1376-1385
9. Gaze S.T., Dutra W.O., Lessa M., Lessa H., Guimarães L.H., Jesus A.R., et al. Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol 63 (2006) 70-78
10. Gladkevich A., Kauffman H.F., and Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuro-psychopharmacol Biol Psychiatry 28 (2004) 559-576
11. Goodwin F.K., and Jamison K.R. Manic-depressive illness (1990), Oxford University Press, New York
12. Grebb J.A., Girault J.A., Ehrlich M., and Greengard P. Chronic treatment of rats with SCH-23390 or raclopride does not affect the concentrations of DARPP-32 or its mRNA in dopamine-innervated brain regions. J Neurochem 55 (1990) 204-207
13. Guitart X., and Nestler E.J. Chronic administration of lithium or other antidepressants increases levels of DARPP-32 in rat frontal cortex. J Neurochem 59 (1992) 1164-1167
14. Henneberg A., Riedl B., Dumke H.O., and Kornhuber H.H. T-lymphocyte subpopulations in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 239 (1990) 283-284
15. 2+ currents and excitability via a novel PLC [beta]1-IP3-calcineurin-signaling cascade. J Neurosci 20 (2000) 8987-8995
16. Horacek J., Bubenikova-Valesova V., Kopecek M., Palecinek T., Dockery C., Mohr P., et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20 (2006) 389-409
17. Huang H.B., Horiuchi A., Watanabe T., Shih S.R., Tsay H.J., Li H.C., et al. Characterization of the inhibition of protein phosphatase-1 by DARPP-32 and inhibitor-2. J Biol Chem 274 (1999) 7870-7878
18. Ishikawa M., Mizukami K., Iwakiri M., and Asada T. Immunohistochemical and immunoblot analysis of Dopamine and cyclic AMP-regulated phosphoprotein, relative molecular mass 32,000 (DARPP-32) in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Prog Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 1177-1181
19. Kessler R.C., Chiu W.T., and Demler O. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry 62 (2005) 617-627
20. Lang U.E., Puls I., Muller D.J., Strutz-Seebohm N., and Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem 20 (2007) 687-702
21. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. What does the PANSS mean. Schizophr Res 79 (2005) 231-238
22. Manji H.K., and Lenox R.H. Signaling: cellular insights into pathophysiology of bipolar disorder. Biol Psychiatry 48 (2000) 518-530
23. McGurk S.R., Mueser K.T., Harvey P.D., LaPuglia R., and Marder J. Cognitive and symptom predictors of work outcomes for clients with schizophrenia in supported employment. Psychiatr Serv 54 (2003) 1129-1135
24. Meredith E.J., Chamba A., Holder M.J., Barnes N.M., and Gordon J. Close encounters of the monoamine kind: immune cells betray their nervous disposition. Immunology 115 (2005) 289-295
25. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 134 (1979) 382-389
26. Nairn A.C., Svenningsson P., Nishi A., Fisone G., Girault J.A., and Greengard P. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 47 (2004) 14-23
27. Nikkila H.V., Muller K., Ahokas A., Rimon R., and Andersson L.C. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res 49 (2001) 99-105
28. Nishi A., Snyder G.L., and Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17 (1997) 8147-8155
29. Pellicano C., Buttarelli F.R., Circella A., Tiple D., Giovannelli M., Benincasa D., et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson's disease from essential tremor. J Neural Transm 114 (2007) 935-938
30. Reis H.J., Rosa D.V., Guimarães M.M., Souza B.R., Barros A.G., Pimenta F.J., et al. Is DARPP-32 a potential therapeutic target. Expert Opin Ther Targets 11 (2007) 649-661
31. Rosa D.V., Souza R.P., Souza B.R., Motta B.S., Caetano F., Jornada L.K., et al. DARPP-32 expression in rat brain after electroconvulsive stimulation. Brain Res 1179 (2007) 35-41
32. Schindler L., Leroux M., Beck J., Moises H.W., and Kirchner H. Studies of cellular immunity, serum interferon titers, and natural killer cell activity in schizophrenic patients. Acta Psychiatr Scand 73 (1986) 651-657
33. Seeman P., Schwarz J., Chen J.F., Szechtman H., Perreault M., McKnight G.S., et al. Psychosis pathways converge via D2high dopamine receptors. Synapse 60 (2006) 319-346
34. Souza B.R., Souza R.P., Rosa D.V., Guimaraes M.M., Correa H., and Romano-Silva M.A. Dopaminergic intracellular signal integrating proteins: relevance to schizophrenia. Dialogues Clin Neurosci 8 (2006) 95-100
35. Souza R.P., Rosa D.V., Souza B.R., and Romano-Silva M. DARPP-32. AfCS-Nature Molecule Pages (2006) 10.1038/mp.a000752.01
36. Souza, B.R., Torres, K.C., Miranda, D.M., Motta, B.S., Scotti-Muzzi, E., Guimarães, M.M., et al. Study of DARPP-32 and NCS-1 levels in PC12 cells overexpressing NCS-1 treated with typical or atypical antipsychotics 2008; In preparation.
37. Sperner-Unterweger B., Whitworth A., Kemmler G., Hilbe W., Thaler J., Weiss G., et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr Res 38 (1999) 61-70
38. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B.B., et al. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc Natl Acad Sci U S A 97 (2000) 1856-1860
39. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn A.C., and Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44 (2004) 269-296
40. Torres K.C., Antonelli L.R., Souza A.L., Teixeira M.M., Dutra W.O., and Gollob K.J. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations and cytokine profiles from human PBMC. J Neuroimmunol 166 (2005) 144-157
41. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M., and Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. Arch Neurol 64 (2007) 1575-1579
42. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
43. Young R.C., Biggs J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133 (1978) 429-435